FDA backtracks and agrees to review Moderna mRNA flu vaccine after initial rejection

WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of-its-kind shot.

Moderna announced the change Wednesday, about a week after revealing that the FDA’s vaccine chief was refusing to review the new vaccine, made with Nobel Prize-winning mRNA technology.

The dispute centered over a 40,000-person clinical trial that concluded Moderna’s...